Stonepine Capital Management LLC Acquires New Holdings in KalVista Pharmaceuticals, Inc. $KALV

Key Points

• Stonepine Capital Management LLC has acquired a new stake in KalVista Pharmaceuticals, purchasing 21,550 shares valued at approximately $249,000.
• KalVista Pharmaceuticals reported a loss of $3.69 EPS for the last quarter, significantly missing analysts’ expectations.
• Analysts have set new price targets for KalVista Pharmaceuticals, with JMP Securities raising its target from $19.00 to $27.00 and categorizing it as "market outperform."

Stonepine Capital Management LLC acquired a new stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 21,550 shares of the specialty pharmaceutical company's stock, valued at approximately $249,000.

A number of other institutional investors have also recently bought and sold shares of the company. Suvretta Capital Management LLC grew its holdings in KalVista Pharmaceuticals by 16.6% during the fourth quarter. Suvretta Capital Management LLC now owns 4,913,012 shares of the specialty pharmaceutical company's stock valued at $41,613,000 after purchasing an additional 701,007 shares during the period. Tang Capital Management LLC grew its holdings in KalVista Pharmaceuticals by 13.2% during the fourth quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company's stock valued at $41,451,000 after purchasing an additional 572,300 shares during the period. Frazier Life Sciences Management L.P. grew its holdings in KalVista Pharmaceuticals by 32.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company's stock valued at $41,400,000 after purchasing an additional 1,200,000 shares during the period. Vestal Point Capital LP grew its holdings in KalVista Pharmaceuticals by 19.3% during the fourth quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company's stock valued at $40,402,000 after purchasing an additional 770,000 shares during the period. Finally, Vanguard Group Inc. grew its holdings in KalVista Pharmaceuticals by 1.9% during the first quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company's stock valued at $26,526,000 after purchasing an additional 43,355 shares during the period.

KalVista Pharmaceuticals Stock Performance

Shares of KALV opened at $13.41 on Friday. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $16.32. The firm's 50 day moving average price is $13.40 and its two-hundred day moving average price is $12.34. The firm has a market cap of $669.83 million, a P/E ratio of -3.63 and a beta of 0.05.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last announced its quarterly earnings data on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($2.86). During the same period last year, the company earned ($1.07) EPS. On average, sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on KALV shares. JMP Securities boosted their price objective on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a "market outperform" rating in a report on Tuesday, July 8th. Leerink Partners lifted their price target on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, July 7th. Finally, HC Wainwright lifted their price target on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $26.29.

Insider Activity at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 32,979 shares of the business's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total value of $517,440.51. Following the sale, the chief executive officer owned 369,595 shares of the company's stock, valued at $5,798,945.55. The trade was a 8.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.50% of the stock is currently owned by corporate insiders.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.